

## Pancreatic Cancer Committee meeting 6 Day 1

**Date:** 25/10/2016

**Location:** RCOG, London

**Minutes:** Confirmed

<b>Committee members present:</b>		
John Primrose (Chair)		(Present for notes 1 – 5)
John Neoptolemos (Clinical Lead)		(Present for notes 1 – 5)
Fiona Campbell		(Present for notes 1 – 5)
Margred Capel		(Present for notes 1 – 5)
Richard Charnley		(Present for notes 1 – 5)
Pippa Corrie		(Present for notes 1 – 5)
Lesley Goodburn		(Present for notes 1 – 5)
Philip Whelan		(Present for notes 1 – 5)
Laura McGeeney		(Present for notes 1 – 5)
Somnath Mukherjee		(Present for notes 1 – 5)
Kofi Oppong		(Present for notes 1 – 5)
Suzanne Joharchi		(Present for notes 1 – 5)
Dawn Elliot		(Present for notes 1 – 5)
Mark Callaway		(Present for notes 1 – 5)

<b>In attendance:</b>		
Angela Bennett	NGA Guideline Lead	(Present for notes 1 – 5)
James Hawkins	NGA Health Economist	(Present for notes 1 – 7)
Matthew Prettyjohns	NGA Senior Health Economist	(Present for notes 1 – 5)
Ferruccio Pelone	NGA Assistant Reviewer	(Present for notes 1 – 5)
Fionnuala O'Brien	NGA Project Manager	(Present for notes 1 – 5)

<b>Observers:</b>	
Thomas Feist	NGA Coordinator

<b>Apologies:</b>	
Anna Jewell	Committee member

Derek O'Reilly	Committee member
John Graham	NGA Clinical Adviser
Katie Perryman Ford	NICE Guideline Commissioning Manager
Linyun Fou	NGA Systematic Reviewer

### 1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the 6<sup>th</sup> meeting on Pancreatic Cancer.

No members of the public asked to observe the meeting.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included: the draft results of a network meta-analysis, reviewing clinical evidence, drafting recommendations and agreeing the content of linking evidence to recommendations tables.

### 2. Declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was pancreatic cancer.

The Chair asked everyone to verbally declare any interests that have arisen since the last meeting.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	He had provided consultancy to Erytech Pharma, France, on product development. This product is not discussed in this guideline and is not near production at this stage.	Financial personal, specific	Declare and participate. The product JN provided consultancy on is not being discussed in this guideline, it is pre-trials stage. It is not felt there will be any conflict of interest

The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the other attendees from fully participating in the meeting.

### **3. Minutes of last meeting**

The Chair asked the Committee if it wanted any changes made to the minutes of the last meeting. The Committee agreed that the minutes were a true and accurate account of the meeting.

The Chair confirmed that all matters arising had been completed or were in hand.

### **4. Presentations**

The Chair introduced James Hawkins, Health Economist, who gave a presentation about the network meta-analysis being conducted for question 5d of the guideline. James then took questions from the group.

The Chair introduced Ferruccio Pelone, Assistant Systematic Reviewer, who gave a presentation on the clinical evidence for question 5g. Ferruccio then took questions from the group. The Committee then discussed the issues presented in relation to this guideline.

The Chair introduced Ferruccio Pelone, Assistant Systematic Reviewer, who gave a presentation on the clinical evidence for question 5i. Ferruccio then took questions from the group. The Committee then discussed the issues presented in relation to this guideline.

### **5. Questions and discussion**

The Committee discussed the clinical evidence presented for questions 5g and 5i and drafted recommendations and the section of the guideline linking evidence to recommendations.

The Committee discussed the reviewed the inclusion/exclusion criteria for the NMA for topic 5d and agree on what they should be.

### **6. Any other business**

No service user or carer concerns were raised.

**Date of next meeting:** 25&26/10/2016

**Location of next meeting:** RCOG, London